A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants in First-Line Metastatic Melanoma (INTerpath-012)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519605-36-00

Acronym

V940-012

Enrollment

Registered

2025-07-30

Start date

2025-08-08

Completion date

Unknown

Last updated

2025-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melanoma

Brief summary

Progression-free survival (PFS)

Detailed description

Objective Response (OR), Duration of Response (DOR), Overall Survival (OS), Number of participants with ≥1 adverse event (AE), Number of participants discontinuing from study therapy due to AE

Interventions

DRUGmRNA-4157

DRUGPlacebo to V940

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-free survival (PFS)	—

Secondary

Measure	Time frame
Objective Response (OR), Duration of Response (DOR), Overall Survival (OS), Number of participants with ≥1 adverse event (AE), Number of participants discontinuing from study therapy due to AE	—

Countries

France, Germany, Greece, Italy, Poland, Portugal, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026